This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Tonix Pharmaceuticals Appoints Donald J. Kellerman Senior Vice President, Clinical Development And Regulatory Affairs

NEW YORK, April 1, 2014 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) today announced the appointment of Donald J. Kellerman, Pharm.D. to the position of Senior Vice President, Clinical Development and Regulatory Affairs. Dr. Kellerman will be responsible for overseeing strategy and execution of Tonix's clinical programs.

"We welcome Don Kellerman to Tonix's executive management team as we bring our headache program into the clinic later this year," said Seth Lederman, MD, president and CEO of Tonix. "His recent and successful experience shepherding a novel formulation of a decades-old agent for migraine through a registration program and a New Drug Application (NDA) submission is reflective of our business approach and will be of great value to Tonix. Our lead program, TNX-102 SL for the management of fibromyalgia, is currently being studied in the BESTFIT trial. We are also developing TNX-102 SL for the treatment of post-traumatic stress disorder. Finally, Tonix is developing TNX-201 for episodic tension-type headache. TNX-201 is a single isomer of isometheptene, which has an extensive history of use in headache in the U.S.," added Dr. Lederman. "Don's experience is uniquely suited to our model."

Dr. Kellerman brings more than 30 years of experience in the development of prescription pharmaceuticals to the Tonix team, spanning several therapeutic areas including central nervous system, respiratory, allergy, ophthalmology and cardiovascular. From 2008 to 2013, Dr. Kellerman served as Senior Vice President, Clinical Development and Medical Affairs at MAP Pharmaceuticals, Inc. (acquired by Allergan, Inc.), where he managed the development of MAP0004 for the treatment of migraine. Prior to joining MAP Pharmaceuticals, Dr. Kellerman held positions at Inspire Pharmaceuticals, Inc. (acquired by Merck & Co., Inc.), Glaxo Wellcome plc, Sepracor, Inc. (acquired by Dainippon Sumitomo Pharma Co., Ltd.), Ciba-Geigy Corporation, and E.R. Squibb and Sons, Inc., and served as project leader for multiple products including Flovent®, Advair®, and Xopenex®.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,003.61 -34.36 -0.19%
S&P 500 2,100.81 -8.11 -0.38%
NASDAQ 5,029.1870 -31.0590 -0.61%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs